They showed that early decrease in TNFR-1 and TNFR-2 during canagliflozin treatment was independently associated with a lower risk of kidney disease progression, suggesting that markers of LGI have the potential to be pharmacodynamic markers of response to SGLT-2i [64]. This evidence concerns the gene TNFRSF1B and kidney disorder.